image

PRT1419 Trials

Proven success in rapidly advancing novel therapeutics to clinical trials for cancer patients.

Phase 1 Study of Oral PRT1419 in Patients with Relapsed/Refractory Hematologic Malignancies — PRT1419-01 (NCT04543305)

Intervention:

Oral PRT1419

Trial Status:

Actively Recruiting

Trial Information:

PRT1419 is designed to be a potent, selective, and orally available inhibitor of the anti-apoptotic protein, myeloid cell leukemia 1 (MCL1). MCL1 has been shown to have a critical role in promoting cancer cell survival and is frequently found to be amplified or overexpressed in both solid tumors and hematologic cancers.

This Phase 1 dose-escalation study of PRT1419 will seek to define the dosing schedule, maximally tolerated dose, and/or estimate the optimal biological dose to be used in subsequent development of PRT1419. The study will enroll patients with certain relapsed/refractory hematologic malignancies, including:

  • High-risk myelodysplastic syndrome (MDS)
  • Acute myeloid leukemia (AML)
  • Chronic myelomonocytic leukemia (CMML)
  • Non-Hodgkin’s lymphoma (NHL)
  • Multiple myeloma (MM)

For full trial information, please visit ClinicalTrials.gov or contact us directly at [email protected].

Phase 1 Study of Intravenous PRT1419 in Patients with Advanced Solid Tumors — PRT1419-02 (NCT04837677)

Intervention:

Intravenous PRT1419

Trial Status:

Actively Recruiting

Trial Information:

PRT1419 is designed to be a potent and selective inhibitor of the anti-apoptotic protein, myeloid cell leukemia 1 (MCL1). MCL1 has been shown to have a critical role in promoting cancer cell survival and is frequently found to be amplified or overexpressed in both solid tumors and hematologic cancers.

This Phase 1 dose-escalation study of PRT1419 will seek to define the dosing schedule, maximally tolerated dose, and/or estimate the optimal biological dose to be used in subsequent development of PRT1419. The study will enroll patients with certain relapsed/refractory solid tumors, including:

  • Sarcoma
  • Melanoma
  • Lung cancer
  • Breast cancer
  • Esophageal cancer
  • Cervical cancer
  • Head and neck cancer

For full trial information, please visit ClinicalTrials.gov or contact us directly at [email protected].

Phase 1 Study of Intravenous PRT1419 in Patients with Relapsed/Refractory Hematologic Malignancies — PRT1419-03 (NCT05107856)

Intervention:

Intravenous PRT1419

Trial Status:

Actively Recruiting

Trial Information:

PRT1419 is designed to be a potent and selective inhibitor of the anti-apoptotic protein, myeloid cell leukemia 1 (MCL1). MCL1 has been shown to have a critical role in promoting cancer cell survival and is frequently found to be amplified or overexpressed in both solid tumors and hematologic cancers.

This Phase 1 dose-escalation study of PRT1419 will seek to define the dosing schedule, maximally tolerated dose, and/or estimate the optimal biological dose to be used in subsequent development of PRT1419. The study will enroll patients with certain relapsed/refractory hematologic malignancies, including:

  • High-risk myelodysplastic syndrome (MDS)
  • Acute myeloid leukemia (AML)
  • Chronic myelomonocytic leukemia (CMML)
  • MDS/myeloproliferative (MPN) overlap syndrome

For full trial information, please visit ClinicalTrials.gov or contact us directly at [email protected].